Ganga Pharmaceuticals Limited

Key Dates and Meeting Details

  • 37th Annual General Meeting to be held on Saturday, September 26, 2026 at 4:30 PM
  • Meeting venue: Registered office at Gangatat, Dhanvantri Marg, Gopcharpada, Virar East, Palghar-401305
  • Cut-off date for determining member eligibility: Friday, September 18, 2026
  • Remote e-voting period: September 23, 2026 (9:00 AM) to September 25, 2026 (5:00 PM) through CDSL
  • Book closure: September 20, 2026 to September 26, 2026 (both days inclusive)

Business to be Transacted

Ordinary Business:

1. Adoption of Audited Financial Statements for FY ended March 31, 2026

2. Appointment of Mr. Sanjay Kulkarni (DIN: 00065190) who retires by rotation

Special Business:

3. Re-appointment of Mr. Bharat Brijmohan Sharma as Managing Director & CEO for three years from April 1, 2026 to March 31, 2029

Financial Performance Highlights

| Particulars | FY 2025-26 (₹ in lakhs) | FY 2024-25 (₹ in lakhs) | Change |

| Total Income | 310.70 | 307.33 | +1.10% |

| Total Expenditure | 297.77 | 297.86 | -0.03% |

| Profit Before Tax | 12.93 | 9.47 | +36.53% |

| Tax Expense | 2.78 | 1.57 | +77.07% |

| Profit After Tax | 10.15 | 7.90 | +28.48% |

Capital Structure Changes

  • Authorized share capital: ₹750.00 lakhs (75,00,000 equity shares of ₹10 each)
  • Paid-up equity share capital as at March 31, 2026: ₹591.15 lakhs (59,11,500 equity shares)
  • During FY26, company issued 10,75,000 equity shares of ₹10 each at ₹14 per share (including premium of ₹4) through exercise of convertible warrants
  • Money received against share warrants: Nil as on March 31, 2026 (was ₹62.13 lakhs as on March 31, 2025)

Managing Director Re-appointment Details

  • Mr. Bharat Brijmohan Sharma (DIN: 00077026) proposed for re-appointment as MD & CEO
  • Term: Three years from April 1, 2026 to March 31, 2029
  • Remuneration: Not exceeding ₹21.60 lakhs per annum (same as FY26)
  • Additional perquisites: Conveyance allowance, medical reimbursement, LTA, company car, telephone, PF, gratuity, leave encashment
  • No sitting fees for board/committee meetings
  • Minimum remuneration clause included for years with inadequate profits

Board Composition and Directors

Board of Directors as on March 31, 2026:

  • Mr. Sanjay Vyankatesh Kulkarni (Non-Executive Chairman)
  • Mr. Bharat Brijmohan Sharma (Managing Director & CEO)
  • Mrs. Srijna Bharat Sharma (Whole-time Director)
  • Mr. Munna Baijnath Chaurasia (Independent Director)
  • Mr. Aman Mukesh Chaudhari (Independent Director)

Key Managerial Personnel:

  • Mr. Anagh Sharma (Chief Financial Officer)
  • Mrs. Priti Bhaiya (Company Secretary & Compliance Officer)

Dividend and Reserves

  • No dividend recommended for FY 2025-26 to conserve resources
  • Entire profit of ₹10.15 lakhs retained in profit and loss account
  • No amount transferred to General Reserves

Corporate Governance

  • Company listed on BSE SME segment
  • Exempt from certain corporate governance provisions under Regulation 15(2)(b) of SEBI LODR Regulations
  • Maintains three statutory committees: Audit Committee, Stakeholders Relationship Committee, Nomination and Remuneration Committee

Shareholding Pattern

Promoter Shareholding:

  • Bharat Sharma: 14,56,585 shares (24.64%)
  • Srijana Sharma: 4,41,905 shares (7.48%)
  • Anagh Sharma: 3,60,000 shares (6.09%)
  • Sharma Brijmohan HUF: 3,49,500 shares (5.91%)

Other Significant Shareholders:

  • Lenus Finvest Pvt. Ltd.: 3,75,000 shares (6.34%)
  • Plutus Capital Management LLP: 3,75,000 shares (6.34%)
  • Bhavesh Dhirajlal Tanna: 3,91,000 shares (6.61%)
  • Prakash Dhirajlal Tanna: 3,25,000 shares (5.50%)

Other Material Information

  • Company engaged in manufacturing & trading of Ayurvedic pharmaceutical products
  • No subsidiaries, associates or joint ventures
  • No foreign investments or collaborations
  • Industrial relations remained peaceful and harmonious during the year
  • No sexual harassment complaints filed or pending during FY26
  • CSR provisions not applicable to the company

Forward-looking Statements

Management Discussion & Analysis highlights growth opportunities in Indian Ayurvedic market driven by post-pandemic wellness demand, digital adoption, and government support for AYUSH systems. Company focusing on market expansion and product development.